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Intravenous tissue plasminogen activator thrombolysis for stroke is still under use. A substantial proportion of excluded patients
for mild or improving symptoms are dependent at discharge. We prospectively recruited 49 patients who did not receive
thrombolysis because of mild or improving symptoms. 32 had favorable outcome (mRS ≤ 2) and 17 had unfavorable outcome
(mRS > 2) at discharge. Comparisons were made between the two groups. Age was older (72.5 ± 10.0v e r s u s6 4 .7 ± 13.2 years,
P = 0.037), and initial National Institutes of Health Stroke Scale (NIHSS) score (5.7 ± 4.0v e r s u s2 .2 ± 2.1, P<0.001) was higher
in the unfavorable group. Diastolic blood pressure was higher in the favorable group (98 ± 15 versus 86 ± 18mmHg; P = 0.018).
Atrial ﬁbrillation (3.1 versus 23.5%; P = 0.043) and ipsilateral artery stenosis (21.9 versus 58.8%; P = 0.012) were more frequently
found in the unfavorable group. Percentage of patients excluded from thrombolysis due to improving symptoms was higher in the
unfavorable group (40.6 versus 82.4%; P = 0.005). Initial NIHSS score, but not other factors, was identiﬁed by logistic regression
analysis as a major independent predictor for unfavorable outcome (OR 1.44; 95%CI, 1.03–2.02).
1.Introduction
Patients with minor or rapidly improving neurological signs
are excluded from intravenous tissue plasminogen activator
(tPA) thrombolysis for acute ischemic stroke in current
American Heart Association/American Stroke Association
guideline [1]. A substantial proportion of patients were ex-
cluded for these reasons [2–4]. Many among those patients
weresigniﬁcantlydependentatdischargeorunabletobe dis-
charged home [2, 5]. The aim of this study was to identify
predictors for unfavorable outcome in this patient group.
2. Methods
ChanghuaChristianHospital(CCH)isamedicalcenterwith
1.684 inpatient beds in western Taiwan, in an area with a
population of 1.3 million. CCH is a participant of the na-
tionwide Taiwan Stroke Registry (TSR) that enrolled acute
strokepatientswithin10daysafteronset[6].CodeCCH-tPA
was implemented for thrombolytic therapy in May 2008 in
the hospital and activated 24 hours a day, seven days a week,
at the triage by senior nursing staﬀs when both Cincinnati
Prehospital Stroke Scale and a set of prescreen criteria are
fulﬁlled. All patients who were excluded from intravenous
thrombolysis due to mild or rapidly improving symptoms
were prospectively recruited for analysis. Mild symptom was
deﬁned as National Institute of Health Stroke Scale (NIHSS)
score lower than 4. Rapidly improving symptom was deﬁned
as regression of neurological symptoms between stroke onset
and evaluation by the treating neurologist.
Any known history or newly found atrial ﬁbrillation was
recorded. Carotid duplex and/or magnetic resonant angiog-
raphy (MRA) was used to identify vascular stenosis. Any
ipsilateral extracranial or intracranial artery stenosis more
than 50% was deﬁned as artery stenosis.
Favorable outcome was deﬁned as modiﬁed Rankin scale
(mRS) score2 at discharge. Unfavorable outcome was
deﬁned as mRS>2 at discharge. Analyses for comparisons2 ISRN Neurology
were made between groups with favorable and unfavorable
outcomes. Independent predictors for unfavorable outcome
were further identiﬁed by binary logistic regression analysis.
Statistical analyses were performed with SPSS for Windows,
version 13.0. The χ2 and Fisher exact tests were used to com-
pare dichotomous variables, and the unpaired, 2-tailed t-test
was used to compare continuous variables.
3. Results
Between May 2008 and February 2010, 368 patients with
acute ischemic stroke or TIA were admitted to our hospital
within 3 hours of symptom onset. Fifty one were ex-
cluded from intravenous thrombolysis due to mild or rap-
idly improving symptoms. Two patients were excluded from
this analysis: one left the hospital against medical advice,
the other was severely disable before stroke due to femoral
fracture. Forty-nine patients were included in this analysis.
Among the included patients, 22 were excluded from throm-
bolysis due to mild symptoms and 27 due to improving
symptoms. The initial NIHSS score was 1.9±1.3 in those
with mild symptoms and 4.6±3.9 in those with improving
symptoms. The diﬀerence of initial NIHSS score between the
two groups was not statistically signiﬁcant (P=0.237).
Among 49 patients, 32 had favorable outcome, and 17
had unfavorable outcome at discharge (Table 1). Age was
older (72.5±10.0 versus 64.7±13.2 years, P=0.037), and
initial NIHSS score (5.7±4.0 versus 2.2±2.1, P<0.001) was
higherintheunfavorablegroup.Diastolicbloodpressurewas
signiﬁcantly higher in the favorable group (98±15 versus
86±18mmHg;P=0.018).Electrocardiographyandvascular
study were performed in high proportion of patients in both
groups. Atrial ﬁbrillation (3.1 versus 23.5%; P=0.043) and
ipsilateral artery stenosis (21.9 versus 58.8%; P=0.012) were
more frequently found in the unfavorable group. Percentage
of patients excluded from thrombolysis due to improving
symptoms was higher in the unfavorable group (40.6 versus
82.4%; P=0.005).
Further logistic regression analysis identiﬁed initial
NIHSS score, but not other factors, as an independent pre-
dictorforunfavorableoutcome(OR1.44;95%CI,1.03–2.02)
(Table 2, model 1). Using dichotomous NIHSS score (at 3)
in the regression analysis demonstrated high risk of unfavor-
ableoutcome(OR5.95;95%CI,1.10–32.12)forpatientswith
initialNIHSSscore  3.Nootherfactorsindependentlypre-
dicted unfavorable outcome, including improving symptom
(Table 2,m o d e l2 ) .
4. Discussion
In tPA thrombolytic therapy for acute ischemic stroke, exclu-
sion criteria “mild neurological impairment” and “rapidly
improving symptoms” were not clearly deﬁned and left to
the clinicians’ interpretation. A proportion of stroke pa-
tients are not receiving thrombolytic therapy due to these
exclusion criteria. Some studies aimed at identifying patients
w h oa r ee x c l u d e db u tw i l lb e n e ﬁ tf r o mt h et r e a t m e n t[ 7, 8].
A post hoc subgroup analyses from the NINDS rt-PA Stroke
Table 1: Characteristics of patients in the groups of favorable and
unfavorable outcome.
Favorable Unfavorable P
No 32 17
Age, years 64.7±13.2 72.5±10.0 0.037
Female sex 10 (31.3) 9 (52.9) 0.138
Initial presentations
NIHSS 2.2±2.1 5.7±4.0 <0.001
Improving symptoms∗ 13 (40.6) 14 (82.4) 0.005
Systolic BP, mmHg 170±26 162±26 0.261
Diastolic BP, mmHg 98±15 86±18 0.018
Glucose, mg/dL 158±64 151±50 0.724
Risk factors
Atrial ﬁbrillation 1 (3.1) 4 (23.5) 0.043
Artery stenosis 7 (21.9) 10 (58.8) 0.012
Hypertension 23 (71.9) 14 (82.4) 0.417
Diabetes 9 (28.1) 8 (47.1) 0.185
Previous stroke 5 (15.6) 4 (23.5) 0.700
Smoking habit 14 (43.8) 5 (29.4) 0.327
Outcome at discharge
NIHSS 1.4±1.3 5.3±3.3 <0.001
mRS 1.2±0.6 3.4±0.5 <0.001
Barthel index 95.7±8.4 57.7±23.9 <0.001
Examinations
MRA 16 (50.0) 12 (70.6) 0.166
Carotid duplex 28 (87.5) 17 (100.0) 0.248
MRA or duplex 29 (90.6) 17 (100.0) 0.542
EKG 32 (100.0) 17 (100.0) —
∗Number of patients excluded from thrombolysis due to improving
symptoms. Continuous variables are median ± standard deviation.
Numbers in parenthesis denote percentage.
Table 2: Logistic regression analyses for unfavorable outcome.
Odds ratio 95% C.I. P
Model 1
NIHSS score 1.44 1.03–2.02 0.034
Age 1.03 0.95–1.12 0.493
DBP 0.96 0.91–1.02 0.229
Atrial ﬁbrillation 11.56 0.63–211.75 0.099
Artery stenosis 1.69 0.29–9.79 0.561
Improving symptom 2.29 0.37–14.02 0.372
Model 2
NIHSS 3v e r s u s<3 5.95 1.10–32.12 0.038
Age 1.04 0.95–1.12 0.459
DBP 0.96 0.91–1.02 0.216
Atrial ﬁbrillation 5.21 0.24–110.98 0.290
Artery stenosis 2.57 0.45–14.61 0.285
Improving symptom 2.94 0.49–17.59 0.237
Study group showed that no diﬀerence was detected in
the beneﬁcial eﬀects of tPA in patients with 5 diﬀerentISRN Neurology 3
deﬁnitionsofminorstrokesyndromescomparedtotheover-
all treatment eﬀects in the entire cohort [7]. 32 patients with
mild symptoms with aphasia representing the most com-
mon symptom were treated with intravenous thrombolysis.
Outcome was favorable. Patients with mild but disabling
symptoms were suggested to be treated with tPA regardless
of their baseline NIHSS score [8].
An operational deﬁnition of “mild neurological impair-
ment” seems not to be feasible based on NIHSS score.
However, an international survey on the inclusion and ex-
clusion criteria for tPA thrombolysis reached a consensus on
a minimal NIHSS score of 2 to 3 to warrant treatment [9].
Our study demonstrated that patients with initial NIHSS
score above this limit had 5.95 times risk to have unfavorable
outcome. On the contrary, consensus was not reached in the
survey on rapidly improving symptoms. A study on patients
who were excluded from tPA treatment due to mild or im-
proving symptoms showed that patients who had 4-point
improvement in NIHSS score and were excluded from tPA
treatment were more likely to have subsequent neurological
worsening. However, no single variable at presentation was
identiﬁed to be associated with death or lack of home dis-
charge [5]. In our study, we identiﬁed initial NIHSS score as
the sole predictor for unfavorable outcome in patients who
were excluded from tPA treatment because of mild or rapidly
improving symptoms.
A study on thrombolytic treatment to 19 acute stroke pa-
tients with rapid early improvement of neurological deﬁcit
showed no neurological deterioration during hospitalization
and good outcomes. The NIHSS score before treatment was
5( 4t o6 )[ 10]. A high proportion of excluded patients in
our study (34.7%) had unfavorable outcome. Treatment for
patients with higher initial NIHSS score, regardless of re-
gressing symptoms, seems to be justiﬁed. Thus, we propose
that “rapidly improving symptoms” may be removed from
the exclusion criteria for intravenous tPA thrombolysis in
stroke patients. Further studies are required to identify a
feasible deﬁnition of “mild symptoms” and justify a cut-oﬀ
point of initial NIHSS score for thrombolytic therapy.
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